受体
抗体
肿瘤坏死因子α
单克隆抗体
兴奋剂
细胞生物学
生物
免疫系统
药理学
癌症研究
免疫学
生物化学
作者
Yanli Yang,Sherry H. Yeh,Shravan Madireddi,Wadim L Matochko,Chen Gu,Patricia Pacheco Sanchez,Mark Ultsch,Gladys De Leon Boenig,Seth F. Harris,Brandon Leonard,Suzie J. Scales,Jing W. Zhu,Erin Christensen,Julie Q. Hang,Randall J. Brezski,Scot Marsters,Avi Ashkenazi,Siddharth Sukumaran,Henry Chiu,Rafael Cubas,Jeong M. Kim,Greg A. Lazar
出处
期刊:mAbs
[Landes Bioscience]
日期:2019-06-20
卷期号:11 (6): 996-1011
被引量:18
标识
DOI:10.1080/19420862.2019.1625662
摘要
Agonism of members of the tumor necrosis factor receptor superfamily (TNFRSF) with monoclonal antibodies is of high therapeutic interest due to their role in immune regulation and cell proliferation. A major hurdle for pharmacologic activation of this receptor class is the requirement for high-order clustering, a mechanism that imposes a reliance in vivo on Fc receptor-mediated crosslinking. This extrinsic dependence represents a potential limitation of virtually the entire pipeline of agonist TNFRSF antibody drugs, of which none have thus far been approved or reached late-stage clinical trials. We show that tetravalent biepitopic targeting enables robust intrinsic antibody agonism for two members of this family, OX40 and DR5, that is superior to extrinsically crosslinked native parental antibodies. Tetravalent biepitopic anti-OX40 engagement co-stimulated OX40low cells, obviated the requirement for CD28 co-signal for T cell activation, and enabled superior pharmacodynamic activity relative to native IgG in a murine vaccination model. This work establishes a proof of concept for an engineering approach that addresses a major gap for the therapeutic activation of this important receptor class.
科研通智能强力驱动
Strongly Powered by AbleSci AI